-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on LENZ Therapeutics, Lowers Price Target to $45

Benzinga·10/29/2026 17:25:54
Listen to the news
TD Cowen analyst Stacy Ku maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $50 to $45.